JONES EVAN/ FA
Known title: DirectorCIK: 0001020741
Associated companies
Transaction History
| VCYT | ▲ Buy | Grant | 5,272 | $0 | 6/11/2026 | View on chart |
| VCYT | ▼ Sell | Open Market | 1,106 | $56K | 11/25/2025 | View on chart |
| VCYT | ▲ Buy | Option Exercise | 10,000 | $79K | 11/5/2025 | View on chart |
| VCYT | ▼ Sell | Open Market | 5,872 | $265K | 11/5/2025 | View on chart |
| VCYT | ▼ Sell | Open Market | 24,296 | $1.1M | 11/5/2025 | View on chart |
| VCYT | ▼ Sell | Open Market | 657 | $30K | 11/5/2025 | View on chart |
| VCYT | ▼ Sell | Open Market | 10,837 | $475K | 11/5/2025 | View on chart |
| VCYT | ▲ Buy | Option Exercise | 10,000 | $76K | 11/5/2025 | View on chart |
| VCYT | ▼ Sell | Open Market | 408 | $17K | 11/5/2025 | View on chart |
| VCYT | ▼ Sell | Open Market | 1,126 | $48K | 11/5/2025 | View on chart |
| VCYT | ▲ Buy | Option Exercise | 10,000 | $53K | 11/5/2025 | View on chart |
| VCYT | ▲ Buy | Grant | 9,321 | $0 | 6/18/2025 | View on chart |
| VCYT | ▼ Sell | Open Market | 5,173 | $182K | 9/19/2024 | View on chart |
| VCYT | ▲ Buy | Option Exercise | 8,486 | $88K | 8/13/2024 | View on chart |
| VCYT | ▼ Sell | Open Market | 16,838 | $545K | 8/13/2024 | View on chart |
| VCYT | ▼ Sell | Open Market | 2,931 | $91K | 8/13/2024 | View on chart |
| VCYT | ▼ Sell | Open Market | 688 | $23K | 8/13/2024 | View on chart |
| VCYT | ▼ Sell | Open Market | 3,869 | $121K | 8/13/2024 | View on chart |
| VCYT | ▼ Sell | Open Market | 22,407 | $725K | 8/13/2024 | View on chart |
| VCYT | ▼ Sell | Open Market | 912 | $30K | 8/13/2024 | View on chart |
| VCYT | ▼ Sell | Open Market | 99 | $3K | 8/12/2024 | View on chart |
| VCYT | ▼ Sell | Open Market | 101 | $3K | 8/12/2024 | View on chart |
| VCYT | ▲ Buy | Option Exercise | 300 | $3K | 8/9/2024 | View on chart |
| VCYT | ▼ Sell | Open Market | 1,032 | $31K | 8/9/2024 | View on chart |
| VCYT | ▼ Sell | Open Market | 746 | $22K | 8/9/2024 | View on chart |
| VCYT | ▲ Buy | Option Exercise | 1,214 | $13K | 8/7/2024 | View on chart |
| VCYT | ▼ Sell | Open Market | 5,108 | $155K | 8/7/2024 | View on chart |
| VCYT | ▲ Buy | Grant | 11,473 | $0 | 6/13/2024 | View on chart |
| VCYT | ▲ Buy | Option Exercise | 10,000 | $132K | 3/1/2024 | View on chart |
| VCYT | ▼ Sell | Open Market | 10,000 | $244K | 3/1/2024 | View on chart |
| VCYT | ▼ Sell | Open Market | 838 | $25K | 7/19/2023 | View on chart |
| VCYT | ▼ Sell | Open Market | 3,090 | $93K | 7/19/2023 | View on chart |
| VCYT | ▼ Sell | Open Market | 2,324 | $70K | 7/18/2023 | View on chart |
| VCYT | ▼ Sell | Open Market | 7,441 | $225K | 7/18/2023 | View on chart |
| VCYT | ▼ Sell | Open Market | 19,095 | $574K | 7/17/2023 | View on chart |
| VCYT | ▼ Sell | Open Market | 23,949 | $720K | 7/17/2023 | View on chart |
| VCYT | ▲ Buy | Grant | 9,674 | $0 | 6/9/2023 | View on chart |
| VCYT | ▼ Sell | Open Market | 600 | $18K | 12/14/2022 | View on chart |
| VCYT | ▼ Sell | Open Market | 1,367 | $42K | 12/13/2022 | View on chart |
| VCYT | ▼ Sell | Open Market | 300 | $9K | 12/13/2022 | View on chart |
| VCYT | ▼ Sell | Open Market | 5,900 | $178K | 11/11/2022 | View on chart |
| VCYT | ▼ Sell | Open Market | 100 | $3K | 11/11/2022 | View on chart |
| VCYT | ▲ Buy | Grant | 14,731 | $0 | 6/16/2022 | View on chart |
| VCYT | ▲ Buy | Option Exercise | 5,000 | $20K | 1/11/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
Veracyte (VCYT) Stock Seen as Undervalued After 107% Rise
Recent coverage notes that Veracyte’s shares have risen more than 100% while still appearing inexpensive relative to its earnings multiple. The company’s trailing P/E of about 30.6 and an analyst consensus target near $58 suggest the market may be pricing in further upside. The stock is currently trading near the lower end of its 52‑week range, close to a support level that has been tested multiple times.
Veracyte (VCYT) Stock Seen as Undervalued After 107% Rise. Recent coverage notes that Veracyte’s shares have risen more than 100% while still appearing inexpensive relative to its earnings multiple. The company’s trailing P/E of about 30.6 and an analyst consensus target near $58 suggest the market may be pricing in further upside. The stock is currently trading near the lower end of its 52‑week range, close to a support level that has been tested multiple times.